Smartwatch could spot nerve damage before it starts

NCT ID NCT06052345

First seen Aug 14, 2026 ยท Last updated Aug 14, 2026

Summary

This study follows women with early-stage breast cancer who are about to receive paclitaxel chemotherapy, a treatment that often causes nerve damage. Researchers will use smartwatches and a mobile app to track physical activity, sleep, and stress, alongside clinical exams and skin biopsies. The goal is to find early warning signs of nerve damage and understand how it affects quality of life over a year.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Garmin smartwatch and REBECCA mobile app for monitoring physical activity, sleep, stress, and location patterns
What this could lead to
If successful, this could lead to early detection and prevention of chemotherapy-induced nerve damage, improving quality of life for breast cancer patients.
What could go wrong
This is an observational study, so it won't test a treatment. It may not find clear predictors, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Karolinska University Hospital

    Solna, Stockholm County, 171 76, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.